9 minute read
How Hi Doctor's Electronic Prescriptions Work Across the EU
An electronic prescription from an EU-licensed Hi Doctor doctor can support care across borders, but dispensing is never automatic. Here is how it works, what pharmacists check, common reasons for delay or refusal, and what the doctor re…
DIRECT ANSWER
An online consultation lets an EU-licensed doctor review your case and, if appropriate, issue an electronic prescription; each pharmacy decides whether it can dispense it.
Doctor reply in under 2 hours
Average doctor reply under 2 hours; at night and on public holidays it can take longer, always within 24 hours. A prescription only if appropriate.
EU-licensed doctors
Every case is reviewed by an EU-licensed doctor.
Electronic prescription
Each pharmacy decides whether it can dispense an approved prescription; some do not accept PDF prescriptions.
HOW IT WORKS
From consultation to collection
- 1
Consultation
Answer a secure medical questionnaire online.
- 2
Doctor reviews
An EU-licensed doctor personally assesses your case.
- 3
Prescription only if appropriate
The doctor replies in under 2 hours on average and issues a prescription only if it is clinically appropriate.
- 4
Collect at the pharmacy you choose
Take an approved prescription to the pharmacy you choose; each pharmacy decides whether it can dispense it.
A valid electronic prescription from an EU-licensed doctor can sometimes be used in another EU country, but acceptance is not guaranteed. In practice, the local pharmacist decides whether the prescription meets national rules, whether the medicine is authorised locally, and whether it is safe to dispense.
That means a Hi Doctor electronic prescription can support continuity of care across borders, but patients should expect verification steps and possible substitutions to an equivalent product. The most useful way to think about it is as an EU-recognisable prescription signed by an EU-licensed doctor, not a guarantee of supply in every pharmacy.
Key point: Hi Doctor electronic prescriptions are issued by EU-licensed doctors and can be presented for cross-border use.
Key point: EU rules support recognition of prescriptions issued in another member state, but local pharmacy law still applies.
Key point: A pharmacist in another EU country may dispense an equivalent medicine with the same active ingredient and strength, if appropriate.
Key point: A licensed doctor must first decide that treatment is clinically appropriate; a prescription is never automatic.
Don't see your condition on Hi-Doctor yet?
Hi-Doctor is continuously onboarding EU-licensed specialists across new conditions. Register your interest and we'll notify you the moment a doctor is available for your case. In the meantime, see how the service works: €25 online consultation, reply within 24 h, full refund if the doctor decides the treatment isn't appropriate.
How Hi Doctor supports cross-border recognition
Hi Doctor issues electronic prescriptions through EU-licensed doctors. The prescription is designed to create a secure, traceable record with the clinical and professional details a pharmacist needs to assess authenticity and appropriateness.
In several EU countries, including Italy, France, Belgium and Ireland, Hi Doctor connects with the local prescription system; elsewhere the patient receives an electronic prescription signed by an EU-licensed doctor, and each pharmacy reviews it and decides whether it can dispense it.
For cross-border use in the EU, the legal backdrop is Directive 2011/24/EU on patients’ rights in cross-border healthcare and the European Commission’s implementing rules on the recognition of prescriptions issued in another member state. These rules aim to make prescriptions understandable across borders by emphasising clear patient identification, prescriber identification, and medicine details.
In practical terms, a cross-border-ready prescription should clearly state the medicine’s active ingredient using the International Nonproprietary Name, often abbreviated to INN. This matters because brand names vary between countries, while the active ingredient, strength, and dosage form are the details a pharmacist relies on to identify a suitable local equivalent.
| Prescription element | Why it matters at an EU pharmacy | Typical example |
|---|---|---|
| Patient identification | Confirms who the medicine is for | Full name and date of birth |
| Prescriber identification | Allows verification of professional status | Doctor’s name, qualification, contact details, country of practice |
| Medicine by active ingredient | Helps the pharmacist find a local equivalent | INN rather than only a brand name |
| Strength and dosage form | Reduces dispensing errors | 50 mg tablet, 1 mg/mL solution |
| Directions and quantity | Supports safe supply and duration of use | Take once daily for 30 days |
Directive 2011/24/EU was introduced to improve continuity of care when patients receive healthcare or prescriptions across EU borders.
Who is most likely to be able to use one abroad
Cross-border use tends to be smoother when the medicine is commonly prescribed, authorised in the destination country, and not subject to tighter national controls. Routine long-term medicines are often easier for pharmacists to assess than medicines with unusual dosing, high misuse potential, or country-specific restrictions.
A patient is more likely to succeed at the pharmacy if the prescription is complete, legible, recent, and medically coherent with their diagnosis or treatment history. It also helps if they can show ID and, where relevant, supporting documents such as a clinic letter or evidence of prior treatment.
Some prescriptions are more likely to face extra scrutiny. Controlled drugs, medicines with abuse potential, certain injectable therapies, and products that are not marketed in the destination country may be refused even if the prescription itself appears valid.
What happens at the pharmacy, and why outcomes vary
Where Hi Doctor connects with the local prescription system, the pharmacist may be able to validate the electronic prescription through that system. Elsewhere, the process is usually more manual: the pharmacist reviews the prescription, checks the prescriber details, confirms the medicine information, and applies local law.
The pharmacist may then dispense the same branded product if it is available locally, or a local equivalent with the same active ingredient, strength, and dosage form. In some cases, they may contact the prescriber for clarification, especially if the wording, quantity, or instructions are unclear.
Outcomes vary because pharmacy law is still national. EU rules support recognition, but they do not require a pharmacist to supply a medicine if they believe the prescription does not meet local legal standards or if dispensing would be unsafe.
| Step | Where Hi Doctor connects with the local system | Where Hi Doctor issues a signed electronic prescription |
|---|---|---|
| Validation | May use local electronic verification | Usually manual review of prescription and prescriber details |
| Brand matching | Often exact local brand if stocked | Often local equivalent based on active ingredient |
| Speed | Usually same visit if in stock | May be delayed by checks or stock issues |
| Decision-maker | Local pharmacist under national rules | Local pharmacist under national rules |
| Chance of refusal | Lower when prescription is valid and stock exists | Higher if medicine is restricted, unclear, or not authorised locally |
- Patient receives electronic prescription
- Patient presents it at an EU pharmacy
- Pharmacist checks identity and prescription details
- Medicine authorised and legally dispensable locally?
- Details clear and clinically acceptable?
- Pharmacist declines or advises alternative route
- Dispense product or equivalent
- Pharmacist seeks clarification or declines
Realistic timelines, delays, and common reasons for refusal
If a medicine is straightforward and stocked locally, dispensing may happen on the same day. If the pharmacist needs to verify the prescriber or interpret differences in product names, packaging, or dosage forms, it can take longer.
Common reasons for delay include missing prescriber details, a medicine name written only as a brand not sold locally, uncertain dosage instructions, and pharmacy stock shortages. Translation issues can also slow things down if the pharmacist needs to map the prescription to a local product.
Common reasons for refusal include suspicion of fraud, mismatch between the medicine and local dispensing rules, safety concerns, or the medicine being unavailable or unauthorised in that country. Refusal can also happen where extra documentation is needed for a restricted medicine and is not available at the counter.
Even when a prescription is valid, a pharmacist may refuse supply if local law restricts that medicine or if they cannot verify the details safely.
Side-effects, substitutions, and safety points patients often miss
The cross-border issue is not just legal; it is also clinical. When a pharmacist substitutes to a local equivalent, the active ingredient should match, but the brand, tablet appearance, packaging, and patient leaflet may differ.
That can matter if you have allergies or sensitivities to excipients such as lactose, certain dyes, or preservatives. It can also matter if you use devices like pens, inhalers, or patches, where technique and product-specific instructions affect safe use.
Side-effects depend on the medicine itself rather than the country where it is dispensed. Patients should check the strength, dosage form, and directions carefully before leaving the pharmacy, especially if the local equivalent looks unfamiliar.
Seek urgent local medical help if you develop signs of a serious reaction after starting any medicine, such as trouble breathing, swelling of the lips or tongue, severe rash, chest pain, or fainting. For less urgent side-effects, speak to a pharmacist or doctor promptly before continuing if symptoms are significant.
What the EU-licensed doctor reviews before issuing a prescription
A doctor does not simply convert a request into an electronic prescription. Before issuing any prescription, the doctor reviews whether the medicine is appropriate for the patient’s symptoms, diagnosis, medical history, age, current medicines, allergies, and relevant contraindications.
They also consider whether the requested treatment is suitable for remote care, whether any red-flag symptoms need in-person assessment, and whether there is enough information to prescribe safely. If key details are missing, the doctor may ask further questions or decide that prescribing is not appropriate.
Where treatment is appropriate, the prescription needs to be complete enough to support pharmacy review. That includes clear medicine details, dose, quantity, and prescriber information. Even then, final dispensing abroad remains the local pharmacist’s decision.
How Hi-Doctor can help
Hi-Doctor offers online consultations with EU-licensed doctors in Hair Growth, Weight Loss, and Sexual Health. You complete a secure medical questionnaire, and a licensed doctor reviews your case to decide whether treatment is clinically appropriate.
The consultation fee is €25. If the doctor decides treatment is not appropriate, the consultation fee is refunded in full. Hi-Doctor provides consultations and prescriptions only; it does not sell, ship, or deliver medication.
Your interest guides which specialists we add next.
If your treatment isn't yet among Hi-Doctor's covered specialties, register at hi-doctor.ai so a doctor can notify you the moment we can handle your case. Our EU-licensed doctors issue electronic prescriptions that each pharmacy reviews and decides whether it can dispense, and if the doctor decides the treatment isn't appropriate, the €25 consultation fee is refunded automatically.
COMMON QUESTIONS
Frequently asked questions
No. EU law supports recognition of cross-border prescriptions, but dispensing is still governed by national law and the professional judgement of the local pharmacist. A pharmacist may verify, substitute, delay, or refuse supply.
